WO2014153356A1 - Composition de reprogrammation intracellulaire in vivo et méthode de fabrication et d'utilisation de cette dernière - Google Patents

Composition de reprogrammation intracellulaire in vivo et méthode de fabrication et d'utilisation de cette dernière Download PDF

Info

Publication number
WO2014153356A1
WO2014153356A1 PCT/US2014/031080 US2014031080W WO2014153356A1 WO 2014153356 A1 WO2014153356 A1 WO 2014153356A1 US 2014031080 W US2014031080 W US 2014031080W WO 2014153356 A1 WO2014153356 A1 WO 2014153356A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
complex
combinations
nutraceutical
ems
Prior art date
Application number
PCT/US2014/031080
Other languages
English (en)
Inventor
Vincent C. Giampapa
Original Assignee
Life Science Institute, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Science Institute, Llc filed Critical Life Science Institute, Llc
Publication of WO2014153356A1 publication Critical patent/WO2014153356A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the EMS comprises a biguanide generally represented by Structure
  • nutraceutical comprises ginger. Ginger or ginger root is the thizome of the plant Zingiber officinale.
  • nutraceutical comprises a telomere maintenance complex comprising a group of components that individually and/or jointly support maintaining telomeres of the chromosome.
  • the nutraceutical comprises a stem cell maintenance complex comprising a group of components that individually and/or jointly support optimal maintenance of stem cells and gene expression.
  • the stem cell maintenance complex may include, but is not limited to, chlorella algae, spirulina algae, klamath blue-green algae, fuxoxanthin seaweed (whole plant), nori seaweed extract or brown seaweed extract, or combinations thereof.
  • the EMS optionally comprises a carbonaceous material, alternatively a fullerene.
  • Fullerenes comprise any carbonaceous material having a structure of a regular, three-dimensional network of fused carbon rings. Such a network of fused carbon rings can be arranged in any suitable structure. Nonlimiting examples of such structures include cylindrical, spherical, ovoid, oblate and oblong structures.
  • Typical fullerenes include cylindrical carbon nanotubes and icosahedral C60 carbon molecules.
  • the fullerene comprises a C60 of the type depicted in Formula 9.
  • a third embodiment which is the composition of any of the first through second embodiments wherein the pharmaceutical comprises 2-(N-phenethylcarbamimidoyl)guanidine, N,N-dimethylimidodicarbonimidic diamide, pharmaceutically acceptable salts thereof, or combinations thereof.
  • a fourth embodiment which is the composition of any of the first through third embodiments wherein the pharmaceutical is present in an amount of from about 0.1 wt.% to about 99 wt.%.
  • a ninth embodiment which is the composition of the eighth embodiment wherein the aqueous extract comprise less than about 10 wt.% of oxindole alkaloids based on the total weight of the extract.
  • An eighteenth embodiment which is a method comprising administering to a subject the oral formulation of the seventeenth embodiment about one times to about five times daily.
  • a twentieth embodiment which is the method of any of the eighteenth through nineteenth embodiments wherein the subject is experiencing a disorder selected from the group consisting of diabetes, obesity, mental acuity decline, memory loss, vision loss, or combinations thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition comprenant une substance pharmaceutique, un nutraceutique et une éventuelle matière carbonée, la substance pharmaceutique comprenant un biguanide ou un biguanide substitué.
PCT/US2014/031080 2013-03-18 2014-03-18 Composition de reprogrammation intracellulaire in vivo et méthode de fabrication et d'utilisation de cette dernière WO2014153356A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361803000P 2013-03-18 2013-03-18
US61/803,000 2013-03-18
US201361874829P 2013-09-06 2013-09-06
US61/874,829 2013-09-06

Publications (1)

Publication Number Publication Date
WO2014153356A1 true WO2014153356A1 (fr) 2014-09-25

Family

ID=51581494

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/031080 WO2014153356A1 (fr) 2013-03-18 2014-03-18 Composition de reprogrammation intracellulaire in vivo et méthode de fabrication et d'utilisation de cette dernière

Country Status (1)

Country Link
WO (1) WO2014153356A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2714886C1 (ru) * 2017-11-30 2020-02-20 Оптиджинекс, Инк Увеличение длины теломеры в клетке
US10786448B2 (en) 2018-01-18 2020-09-29 Christian Arnold Chewing gum composition comprising polyhexanide
CN114196622A (zh) * 2021-12-15 2022-03-18 爱思迈拓(广州)科技有限公司 富勒烯及其衍生物在细胞重编中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189512A1 (en) * 2005-01-21 2006-08-24 Ehrenkranz Joel R L Compositions containing botanical extracts rich in phlorizin and methods for using such compositions in blood glucose modification and to affect aging
US7758889B1 (en) * 2002-07-24 2010-07-20 Luna Innovations Incorporated Fullerenes in targeted therapies
US20120177730A1 (en) * 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory Receptor Ligand-Based Therapies
WO2012122295A2 (fr) * 2011-03-07 2012-09-13 Ned Biosystems, Inc. Traitement de l'adénocarcinome pancréatique et d'autres cancers d'origine épithéliale
US20120302942A1 (en) * 2004-09-13 2012-11-29 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7758889B1 (en) * 2002-07-24 2010-07-20 Luna Innovations Incorporated Fullerenes in targeted therapies
US20120302942A1 (en) * 2004-09-13 2012-11-29 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20060189512A1 (en) * 2005-01-21 2006-08-24 Ehrenkranz Joel R L Compositions containing botanical extracts rich in phlorizin and methods for using such compositions in blood glucose modification and to affect aging
US20120177730A1 (en) * 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory Receptor Ligand-Based Therapies
WO2012122295A2 (fr) * 2011-03-07 2012-09-13 Ned Biosystems, Inc. Traitement de l'adénocarcinome pancréatique et d'autres cancers d'origine épithéliale

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2714886C1 (ru) * 2017-11-30 2020-02-20 Оптиджинекс, Инк Увеличение длины теломеры в клетке
US10786448B2 (en) 2018-01-18 2020-09-29 Christian Arnold Chewing gum composition comprising polyhexanide
CN114196622A (zh) * 2021-12-15 2022-03-18 爱思迈拓(广州)科技有限公司 富勒烯及其衍生物在细胞重编中的应用
CN114196622B (zh) * 2021-12-15 2024-02-09 爱思迈拓(广州)科技有限公司 富勒烯及其衍生物在细胞重编中的应用

Similar Documents

Publication Publication Date Title
US11331363B2 (en) Phytocomplexes exhibiting multiple, synergistic antioxidant activities useful in foods, dietary supplements, cosmetics and pharmaceutical preparations
EP1986613B1 (fr) Preparation pharmaceutique a base de microcomprimes
EP3130336A1 (fr) Aliment et/ou composition nutraceutique contenant du pea
US20120225053A1 (en) Compositions and methods for the prevention and treatment of conditions associated with inflamation
Abad et al. Effect of Matricaria chamomilla hydroalcoholic extract on cisplatin-induced neuropathy in mice
US20180133194A1 (en) Method of treating inflammation using natural compounds and/or diet
US10179144B2 (en) Formulations and compositions for rejuvenation of the body
US20230025435A1 (en) Compositions and methods for increasing cellular vitality and longevity and decreasing molecular ageing
WO2014153356A1 (fr) Composition de reprogrammation intracellulaire in vivo et méthode de fabrication et d'utilisation de cette dernière
US20180207113A1 (en) Vivo intracellular reprogramming composition and method of making and using same
US20200093929A1 (en) Pharmaceutical composition for the prevention and treatment of memory and cognitive deficits related to ageing
US20210128492A1 (en) Composition for preventing and/or improving brain dysfunction comprising a lutein or salt thereof and a plant product of the genus trapa
TW201618802A (zh) 用於調控ｐｐ２ａ甲基化反應並提供抗氧化及抗發炎活性之天然萃取物
KR20150129911A (ko) 알파-이소-쿠베베네를 유효성분으로 포함하는 신경 질환의 예방 또는 치료용 조성물
PT2838529E (pt) Composição que compreende ácido alfa-lipóico e honokiol para tratar neuropatias
JP2022509552A (ja) 抗がん用組成物
US20220152140A1 (en) Composition of desmodium and trivalent chromium, and ocular use
KR101637429B1 (ko) 알파-이소-쿠베베놀을 유효성분으로 포함하는 신경 질환의 예방 또는 치료용 조성물
US20230190677A1 (en) Pharmaceutical composition for preventing or treating aging-related diseases
KR102310764B1 (ko) 원화, 위령선, 및 천마의 복합 생약 추출물을 포함하는 신경퇴행성 질환의 예방 또는 치료용 조성물
ES2739133B2 (es) Composicion para la reduccion del declive metabolico asociado al envejecimiento y/o el tratamiento de trastornos relacionados al metabolismo lipidico
Malik Herbal Drugs: A New Hope for Huntington's Disease
WO2020008359A1 (fr) Formulation utilisée pour la prévention et en tant que traitement co-adjuvant de maladies neurodégénératives
WO2023047401A1 (fr) Stratégies d'encapsulation ciblées pour des modalités de traitement
JP2024508110A (ja) 関節炎および乾癬のためのサプリメント

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14769892

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14769892

Country of ref document: EP

Kind code of ref document: A1